Page 2 - Pic1 Valneva News Today : Breaking News, Live Updates & Top Stories | Vimarsana

10.01.2021
Valneva: Valnvea, an Austrian/french specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, reported preliminary and unaudited cash and cash equivalents of Euro 204.4 mn at the end of December 2020, exceeding its guidance of between Euro180 mn and Euro 200 mn. Valneva’s cash and cash equivalents at December 31, 2020 increased to Euro 204.4 mn compared to Euro 64.4 mn at December 31, 2019. The change was primarily driven by a USD 130.0 mn upfront payment related to the Lyme collaboration agreement with Pfizer, Euro 96.7 mn related to the UK COVID-19 vaccine partnership deal, and Euro 48.8 mn of net proceeds from the financing arrangement with Deerfield and OrbiMed, offset by Euro 20 mn repayments of borrowings to the European Investment Bank. Such amounts are preliminary and unaudited.  Thomas Lingelbach, Chief Executive Officer of Valneva commented, “2020 has been a transformational year for Valneva, mar ....

South Korea , United Kingdom , Kauf Valneva , Thomas Lingelbach , Financial Market Authority , Austrian Financial Market Authority , European Investment Bank , European Investment , Chief Executive Officer , Market Authority , Besuchen Sie , Pic1 Valneva , Austrian French , Valneva Amp Rsquo S , Covid 19 , தெற்கு கொரியா , ஒன்றுபட்டது கிஂக்டம் , நிதி சந்தை அதிகாரம் , ஆஸ்திரேலிய நிதி சந்தை அதிகாரம் , ஐரோப்பிய முதலீடு வங்கி , ஐரோப்பிய முதலீடு , தலைமை நிர்வாகி அதிகாரி , சந்தை அதிகாரம் , ஆஸ்திரேலிய பிரஞ்சு , அமெரிக்க டாலர் ,